The drug is MAVYRET, a combination of glecaprevir and pibrentasvir, and it cures all six genotypes of Hepatitis C in just eight weeks — 56 days — for most treatment-naive patients without cirrhosis. It is the only FDA-approved medication that can eliminate every major strain of HCV in under 60 days, with cure rates exceeding 95 percent across clinical and real-world studies. For a site focused on dementia care and brain health, this matters more than you might think: chronic Hepatitis C infection has been linked in multiple studies to increased risk of cognitive decline and dementia, making the availability of a fast, effective cure relevant to anyone concerned about long-term neurological health.
Another option, Harvoni (ledipasvir/sofosbuvir), can also cure HCV genotype 1 in eight weeks for treatment-naive patients without cirrhosis, with real-world studies showing 96 to 98 percent cure rates in those shorter courses. But MAVYRET’s ability to cover all genotypes in that same window makes it the more broadly applicable choice. Despite these breakthroughs, only about one in three infected adults in the United States has actually been cured — a gap driven not by drug failure but by barriers to access and diagnosis. This article covers how these drugs work, what they cost in 2025 and 2026, who qualifies for the shortest treatment courses, what limitations exist, and why global efforts to eliminate Hepatitis C by 2030 are still falling short despite having a near-perfect cure in hand.
Table of Contents
- Which Drugs Actually Cure Hepatitis C in Under 60 Days?
- Who Qualifies for the Shortest Treatment Course — and Who Does Not
- What Does an Eight-Week Hepatitis C Cure Actually Cost?
- The Connection Between Hepatitis C and Brain Health
- Why Two-Thirds of Infected Americans Still Have Not Been Cured
- A Breakthrough for the Rest of the World
- What Comes Next for Hepatitis C Treatment
- Conclusion
- Frequently Asked Questions
Which Drugs Actually Cure Hepatitis C in Under 60 Days?
MAVYRET, manufactured by AbbVie, combines two direct-acting antivirals — glecaprevir, which inhibits the NS3/4A protease, and pibrentasvir, which targets the NS5A protein. Together, they attack the virus at two critical points in its replication cycle. The result is a pan-genotypic cure, meaning it works against all six known HCV genotypes, in an eight-week oral regimen for the majority of patients who have not been previously treated and who do not have cirrhosis. that 56-day timeline makes it the fastest broadly effective Hepatitis C treatment available. Harvoni, made by Gilead Sciences, pairs ledipasvir with sofosbuvir and also achieves an eight-week cure, but only for genotype 1, which is the most common strain in the United States.
Clinical trials published in the new England Journal of Medicine demonstrated a 94 percent sustained virologic response at eight weeks, while real-world data pushed that figure to 96 to 98 percent. The distinction matters: if you have genotype 1 and meet the criteria, Harvoni is a proven option. If your genotype is different, or unknown, MAVYRET is the more reliable eight-week path. Both drugs represent a class called direct-acting antivirals, or DAAs, which replaced the older interferon-based treatments that were brutal in their side effects and modest in their success. Current DAAs cure approximately 95 percent of all Hepatitis C cases across all genotypes, with some studies reporting rates as high as 97 percent. The 2025 AASLD-IDSA guidelines list MAVYRET (eight weeks) and Epclusa, or sofosbuvir-velpatasvir (twelve weeks), as the two equally recommended simplified treatment options, both achieving cure rates above 95 percent across all HCV genotypes.
Who Qualifies for the Shortest Treatment Course — and Who Does Not
The eight-week MAVYRET regimen applies specifically to treatment-naive patients without cirrhosis. That distinction is critical. If you have been treated for Hepatitis C before and the previous regimen failed, or if you have progressed to compensated cirrhosis, your doctor will likely extend the course to twelve or even sixteen weeks. The drug still works in those populations, but the shorter timeline does not apply, and assuming it does could lead to undertreated infection and potential resistance. Harvoni’s eight-week course carries similar restrictions: it is limited to genotype 1 patients who are treatment-naive, without cirrhosis, and with a viral load below six million IU/mL.
If your viral load is higher, the recommendation shifts to twelve weeks. These are not arbitrary cutoffs — they come from clinical trial data showing that patients outside these parameters had lower sustained virologic response rates at the shorter duration. Your hepatologist or infectious disease specialist will run the necessary labs to determine which protocol fits. However, one reassuring finding from the research is that cure rates remain near 95 percent even among patients who miss some doses during treatment. That does not mean adherence is unimportant — it means the drugs have a wide enough therapeutic margin that imperfect real-world compliance does not tank their effectiveness. For older adults managing multiple medications or early cognitive symptoms, that built-in forgiveness is a meaningful practical advantage.
What Does an Eight-Week Hepatitis C Cure Actually Cost?
MAVYRET’s list price sits at roughly $13,200 per month, or approximately $26,400 for a full eight-week course. That number, while steep at face value, rarely reflects what patients actually pay. With commercial insurance and AbbVie’s MAVYRET Savings Card, out-of-pocket costs can drop to as low as $5 per month. For Medicare Part D enrollees, costs range from $0 to $2,000 per month depending on the specific plan, while patients who qualify for the Low-Income Subsidy pay just $12.15 per month as of 2025. Medicaid coverage is even more favorable.
Approximately 96 percent of Medicaid plans list MAVYRET as a preferred or exclusive formulary option, with typical patient costs of $20 per month or less. Across all payer types, the average net cost of DAA treatment after discounts and rebates falls between $11,500 and $17,000 per course. A study cited by PhRMA found that the Hepatitis C cure saved Medicaid an estimated $15 billion by preventing downstream costs — liver transplants, cancer treatment, and long-term care — that chronic HCV would have demanded. For someone weighing the cost against the alternative, consider this: untreated chronic Hepatitis C can progress to cirrhosis, liver cancer, and liver failure over a period of decades. The cumulative cost of managing those complications dwarfs the price of an eight-week pill regimen, to say nothing of the toll on quality of life and cognitive function. If cost is a barrier, patient assistance programs from both AbbVie and Gilead, as well as state Medicaid expansions and the new simplified treatment algorithms, are designed to close that gap.
The Connection Between Hepatitis C and Brain Health
For readers of a dementia care and brain health site, the relevance of a Hepatitis C cure extends beyond the liver. Chronic HCV infection is a systemic inflammatory condition, and the virus has been detected in cerebrospinal fluid and brain tissue. Multiple epidemiological studies have found associations between chronic Hepatitis C and increased rates of cognitive impairment, including deficits in attention, memory, and processing speed — symptoms that can mimic or compound early-stage dementia. The mechanism is not fully settled, but the leading hypotheses involve chronic neuroinflammation driven by HCV’s ability to cross the blood-brain barrier, as well as the downstream metabolic effects of liver dysfunction on brain health.
Hepatic encephalopathy, a well-established complication of advanced liver disease, represents the extreme end of this spectrum. But subtler cognitive effects can appear much earlier, even before cirrhosis develops, and they are easy to misattribute to aging or early neurodegeneration in older adults. The practical takeaway is this: if a patient being evaluated for cognitive decline also carries untreated Hepatitis C, curing the infection may be one of the few genuinely reversible contributors to their symptoms. An eight-week course of MAVYRET is a comparatively simple intervention that removes a known source of systemic inflammation and potential neurotoxicity. It will not reverse Alzheimer’s disease, but it can remove a compounding factor that makes cognition worse than it needs to be.
Why Two-Thirds of Infected Americans Still Have Not Been Cured
An estimated 2.5 to 4 million people in the United States are living with chronic HCV infection, and only about one in three has been cured. In 2022 alone, 67,400 new infections occurred in the U.S., and 12,717 people died from HCV-related causes — despite the fact that curative treatment has been available since 2013. The gap is not a failure of pharmacology. It is a failure of systems. The barriers are layered.
Many people with HCV do not know they are infected, because the virus can remain asymptomatic for years or even decades. Screening has historically been inconsistent, particularly among baby boomers born between 1945 and 1965 who carry a disproportionate share of infections, and among people who inject drugs, who face stigma-related obstacles to care. Even when diagnosed, prior authorization requirements, Medicaid restrictions that some states only recently lifted, and the logistical burden of specialist referrals have slowed treatment initiation. The March 2025 publication of the AASLD-IDSA Point of Care Test and Treat Algorithm represents a direct response to this problem. The protocol enables same-day diagnosis and treatment initiation, removing the weeks-long gap between a positive test and the first pill. For populations that are difficult to retain in care — people experiencing homelessness, those with substance use disorders, or older adults with transportation barriers — collapsing that timeline from weeks to hours can be the difference between cure and lost contact.
A Breakthrough for the Rest of the World
The scale of the global problem is staggering: 50 million people worldwide are living with HCV, and roughly 6,000 new infections occur every day. In 2025, the EASE Study published in The Lancet demonstrated that a regimen of ravidasvir plus sofosbuvir achieved non-inferiority to twelve-week courses when given for just eight weeks to patients without cirrhosis, reducing treatment costs by 40 percent. Developed by the Drugs for Neglected Diseases initiative, this combination is specifically designed for low- and middle-income countries where MAVYRET’s pricing, even at discounted tiers, remains out of reach. On March 10, 2026, the WHO launched its first-ever implementation handbook consolidating over 80 evidence-informed recommendations on hepatitis B, C, and D to accelerate the 2030 elimination goal.
As of now, only three countries — Canada, Japan, and Rwanda — have met the WHO target of 90 percent or greater diagnosis coverage. The tools exist. The drugs exist. What remains is the political and logistical will to deploy them at the scale the crisis demands.
What Comes Next for Hepatitis C Treatment
The trajectory of HCV treatment points toward further simplification and broader access. The test-and-treat model endorsed by the AASLD-IDSA in 2025 is likely to become standard practice in primary care settings, not just specialist clinics. Shorter regimens validated by studies like EASE could open the door to even more affordable generic combinations for global use. And ongoing research into pan-genotypic treatments continues to explore whether cure durations can be compressed below eight weeks without sacrificing efficacy.
For the brain health community specifically, the growing recognition that chronic infections contribute to neurodegeneration should sharpen the argument for universal HCV screening among older adults presenting with cognitive complaints. A curable infection that compounds dementia risk is a rare opportunity in a field defined by conditions we cannot yet reverse. The eight-week cure exists. The remaining challenge is making sure it reaches the people who need it.
Conclusion
MAVYRET cures all six genotypes of Hepatitis C in eight weeks with greater than 95 percent efficacy, and Harvoni achieves comparable results for genotype 1 in the same timeframe. These are among the most effective medications ever developed for any infectious disease. The cost, while high at list price, is manageable or negligible for most insured patients, and the downstream savings — in liver disease, cancer prevention, and potentially cognitive health — far exceed the upfront investment.
The harder truth is that having a cure is not the same as deploying one. With roughly two-thirds of infected Americans still untreated and only three countries worldwide meeting WHO diagnosis targets, the bottleneck has shifted entirely from pharmacology to implementation. If you or someone you care for has risk factors for Hepatitis C — particularly older adults with unexplained cognitive changes — a simple blood test is the starting point. The cure that follows takes less than 60 days.
Frequently Asked Questions
Can MAVYRET cure all types of Hepatitis C?
Yes. MAVYRET is the only FDA-approved treatment that cures all six HCV genotypes in an eight-week course for treatment-naive patients without cirrhosis. Cure rates exceed 95 percent across all genotypes.
How much does an eight-week Hepatitis C cure cost out of pocket?
It depends on your insurance. With commercial insurance and the MAVYRET Savings Card, costs can be as low as $5 per month. Medicare Part D patients pay $0 to $2,000 monthly depending on their plan, and Medicaid patients typically pay $20 per month or less. The full list price is approximately $26,400 for the eight-week course.
Does Hepatitis C affect the brain?
Chronic HCV infection has been associated with cognitive impairment, including problems with attention, memory, and processing speed. The virus can cause systemic inflammation and has been detected in brain tissue. Curing HCV may help reduce this inflammatory burden on the brain, though it will not reverse neurodegenerative conditions like Alzheimer’s disease.
What if I have cirrhosis — can I still be cured in eight weeks?
Not with the standard short course. Patients with compensated cirrhosis typically require twelve to sixteen weeks of treatment with MAVYRET or an alternative regimen. The cure rates remain high, but the longer duration is necessary to achieve sustained virologic response in the setting of advanced liver disease.
Who should be screened for Hepatitis C?
The CDC recommends that all adults aged 18 and older be screened at least once, with more frequent testing for people who inject drugs, those born between 1945 and 1965, and anyone with known risk factors. Older adults with unexplained cognitive decline should also be considered for screening, given the emerging links between HCV and brain health.
Are there newer, cheaper treatments being developed?
Yes. The 2025 EASE Study demonstrated that ravidasvir plus sofosbuvir, an eight-week regimen developed by the Drugs for Neglected Diseases initiative, achieved non-inferiority to twelve-week courses and reduced treatment costs by 40 percent. This combination is aimed at expanding access in low- and middle-income countries.
